A RANDOMIZED PHASE III STUDY COMPARING STANDARD FIRST-LINE DOCETAXEL/PREDNISONE TO DOCETAXEL/PREDNISONE IN COMBINATION WITH CUSTIRSEN (OGX-011) IN MEN WITH METASTATIC CRPC.

• • Trial ID: SYNERGY
  • Coordination: Teva/Oncogenex
  • Trial Design: Randomized multicenter study of the addition of custirsen to docetaxel chemotherapy.
  • Patient Population: Metastatic CRPC planned for treatment with docetaxel.
  • Sample size & primary endpoint: n=800, overall survival

AFLIBERCEPT IN COMBINATION WITH DOCETAXEL IN METASTATIC ANDROGEN INDEPENDENT PROSTATE CANCER (VENICE).

• • Trial ID: NCT00519285
  • Coordination: CUOG
  • Trial Design: A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/Prednisone for Metastatic Androgen-independent Prostate Cancer. The objective is to demonstrate an improvement of overall survival in patients treated with aflibercept versus placebo, in patients receiving docetaxel/prednisone. Main secondary endpoints gather prostate-specific antigen (PSA) response, pain re- sponse, time to occurrence of skeletal related events and progression free survival (PFS), as well as safety, pharmacokinetics and immunogenicity.
  • Patient Population: Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer
  • Primary endpoint: Overall survival

PRP-1 – PIN prevention – Fleshner

BL-7 – gem/cis +/- paclitaxel – Winquist

Taxotere + high dose Calcitriol – K Chi

Oncophage in RCC post nephrectomy – Tanguay